Drug
PU-H71
PU-H71 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 40.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
40.0%
Based on 2 completed trials
Completion Rate
40%(2/5)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
3(60%)
Phase Distribution
Ph phase_1
5
100%
Phase Distribution
5
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
40.0%
2 of 5 finished
Non-Completion Rate
60.0%
3 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(2)
Terminated(3)
Detailed Status
Terminated3
Completed2
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
40.0%
Most Advanced
Phase 1
Trials by Phase
Phase 15 (100.0%)
Trials by Status
terminated360%
completed240%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_1
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies
NCT01393509
terminatedphase_1
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
NCT03935555
terminatedphase_1
Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
NCT03373877
completedphase_1
PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer
NCT03166085
terminatedphase_1
PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment
NCT01581541
Clinical Trials (5)
Showing 5 of 5 trials
NCT01393509Phase 1
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies
NCT03935555Phase 1
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
NCT03373877Phase 1
Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
NCT03166085Phase 1
PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer
NCT01581541Phase 1
PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5